Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

196
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
196
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

471
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
471
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

45
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
45
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

51
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
51
Heart Failure IV: Classification and Diagnostic Evaluation01:30

Heart Failure IV: Classification and Diagnostic Evaluation

72
Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
72

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Advancing Quality in the Evaluation, Surveillance, and Management of Aortic Stenosis: A Report From the AHA Target: AS Registry.

Circulation·2026
Same author

Patient Preference Information (PPI) in Medical Device Development: A Cross-Industry Review of Use-Cases.

Therapeutic innovation & regulatory science·2026
Same author

Toward Developing a Patient Reported Outcomes Measure for Children with Heart Failure: A Qualitative Study Design.

American heart journal·2026
Same author

Multidisciplinary approach to implementing ferric carboxymaltose for IV iron replacement in heart failure with iron deficiency.

Future cardiology·2026
Same author

Understanding HPV vaccine preferences among sexual minority men living with HIV in Abuja, Nigeria using a discrete choice experiment.

Vaccine·2026
Same author

Can Large Language Models Predict Patient Treatment Choices? A Discrete Choice Experiment Framework.

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research·2026

Related Experiment Video

Updated: Oct 9, 2025

Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure
05:16

Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure

Published on: June 10, 2025

293

Quantifying Benefit-Risk Preferences for Heart Failure Devices: A Stated-Preference Study.

Shelby D Reed1,2, Jui-Chen Yang2, Timothy Rickert2

  • 1Department of Population Health Sciences (S.D.R., F.R.J., J.M.G.), Duke University School of Medicine, Durham, NC.

Circulation. Heart Failure
|December 23, 2021
PubMed
Summary
This summary is machine-generated.

Heart failure patients show varying risk tolerance for implantable devices. Many accept higher mortality risks for improved function, while others are more risk-averse.

Keywords:
decision makingheart failurepatient preferencerisk assessmentsurveys and questionnaires

More Related Videos

Measuring the Subjective Value of Risky and Ambiguous Options using Experimental Economics and Functional MRI Methods
13:04

Measuring the Subjective Value of Risky and Ambiguous Options using Experimental Economics and Functional MRI Methods

Published on: September 19, 2012

12.2K
Evaluation of Right Ventricular Function in Experimental Models of Pulmonary Arterial Hypertension
10:03

Evaluation of Right Ventricular Function in Experimental Models of Pulmonary Arterial Hypertension

Published on: June 27, 2025

384

Related Experiment Videos

Last Updated: Oct 9, 2025

Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure
05:16

Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure

Published on: June 10, 2025

293
Measuring the Subjective Value of Risky and Ambiguous Options using Experimental Economics and Functional MRI Methods
13:04

Measuring the Subjective Value of Risky and Ambiguous Options using Experimental Economics and Functional MRI Methods

Published on: September 19, 2012

12.2K
Evaluation of Right Ventricular Function in Experimental Models of Pulmonary Arterial Hypertension
10:03

Evaluation of Right Ventricular Function in Experimental Models of Pulmonary Arterial Hypertension

Published on: June 27, 2025

384

Area of Science:

  • Biomedical Engineering
  • Health Services Research
  • Cardiology

Background:

  • Health technology decisions require balancing benefits and risks.
  • Understanding patient risk tolerance is crucial for implantable devices.

Purpose of the Study:

  • To quantify heart failure patients' acceptance of therapeutic risks for improved effectiveness with implantable devices.
  • To inform product development and regulatory decisions by incorporating patient perspectives.

Main Methods:

  • A discrete-choice experiment survey was administered to individuals with heart failure.
  • Participants randomized to choice questions involving device scenarios with varying risks and health outcomes.
  • Logit-based regression models analyzed choices based on health outcomes and risks.

Main Results:

  • Two-thirds of participants were risk-tolerant, accepting up to 9% mortality risk for improved functioning.
  • Approximately 20% were less risk-tolerant, accepting a maximum 3% mortality risk for the same benefit.
  • A minority class showed strong anti-device preferences.

Conclusions:

  • Quantitative data on benefit-risk tradeoffs can guide implantable device development and regulatory processes.
  • Incorporating patient preferences into decision-making is essential for effective health technology implementation.